Allergic Rhinitis / Allergies/Hay Fever / Nasal Care / Sinusitis / Vasoconstrictors

Oksivin-DF 0,01% 10 ml nasal drops

Brands: Dosfarm (Kazakhstan)

$3.50

Quantity

Oksivin-DF 0,01% 10 ml nasal drops quantity

Add to cart

Add to wishlist

Sku:

8998a62076d6

Brands:: Dosfarm (Kazakhstan)

Description

The trade name
of Oksivin-DF

the International unlicensed

name Oxymetazoline Dosage Form
of the Drop nasal 0.01% 10 ml

Structure
of 1 ml of drug contains
active agent – oxymetazoline a hydrochloride – 0.1 mg
excipients: a benzalkoniya chloride (in the form of 10% of solution), sodium chloride, dihydrophosphate sodium a dihydrate, phosphate dinatrium dodecahydrate, water for injections

the Description
Transparent colourless or slightly yellowish solution.

Pharmacotherapeutic group
Nasal drugs. Antikongestanta and other nasal drugs for topical administration. Sympathomimetics. Oxymetazoline
the ATX R01AA05 Code

the Pharmacological

Pharmacokinetics At properties topical administration oxymetazoline in a small amount is soaked up in a system blood stream therefore its concentration in blood plasma is insignificant. Effect of drug is shown in 15 min. after use. Action duration – 10-12 h.
Drug is metabolized only in moderate degree and generally removed from an organism in an invariable view with urine and a stake.
The pharmacodynamics
Oksimetazolin is alpha adrenomimetikom from group of derivatives of imidazoline. Stimulates α1-адренорецепторы. At intranasal use there is a narrowing of blood vessels of a mucous membrane of a nose, hypostasis and hyperaemia of a mucous membrane of a nasopharynx is eliminated. After removal of hypostasis of a mucous membrane the removing channels for aeration of adnexal bosoms of a nose, an acoustical pipe open and extend. It stimulates drainage function of nasal cavities and prevents development of bacterial complications.

Indications
– acute, allergic, vasomotorial rhinitis
– rinosinusit
– the eustachitis associated by rhinitis
– elimination of hypostasis of a mucous membrane of a nasal cavity before the diagnostic

Route of administration procedures and
Intranazalno’s doses.
The cap is unscrewed, removed and, slightly pressed the bottle body.
0.01% of a drop nasal:
– to newborn children of the first 4 weeks of life – on 1 drop in each nasal course 2-3 times a day
– to children from the 5th week to 1 year of life – on 1-2 drops in each nasal course 2-3 times a day.
The following procedure is possible: depending on age 1-2 drops of 0.01% of solution apply on vatu and wipe the nasal courses.
Course of treatment no more than 5-7 days.
It is necessary to watch that when burying the tip of a bottle dropper did not contact to other objects or surfaces. After burying it is dense to close a bottle dropper a cap!

Side effects
often:
– burning and dryness mucous the nasal courses
– dryness in a mouth and a throat
– sneezing
infrequently:
– dizziness, a headache
– insomnia
– fatigue (fatigue)
– nausea
– swelling and hypostasis of a mucous membrane (feeling of congestion of a nose)
– a reactive hyperemia
– a mucosal atrophy
– allergic reactions (Quincke’s edema, urticaria, an itching)
is very rare:
– increase of pulse
– arterial hypertension
– tachycardia
–

the Contraindication tachyphylaxis
– hypersensitivity to drug components
– atrophic rhinitis
– the profound atherosclerosis
– chronic heart failure
– arrhythmias
– arterial hypertension
– chronic kidney disease
– a prostate hyperplasia
– a concomitant use of inhibitors of a monoaminooxidase and the period up to 14 days after the end of their use
– diabetes
– a thyrotoxicosis, a hyperthyroidism
– closed-angle glaucoma
– a serious illness of eyes
– a pheochromocytoma
– the porphyria

Medicinal interactions
Drug slows down absorption of mestnoanesteziruyushchy means and prolongs their effect.
At use of Oksivina-DF with other vasoconstrictors (irrespective of a method of administration) perhaps mutual strengthening of side effects.
Co-administration of inhibitors of a monoaminooxidase (including the period within 14 days after their cancellation) and tricyclic antidepressants can lead to increase in arterial blood pressure.

Special instructions
It is necessary to avoid prolonged use and overdose of Oksivina-DF. Long or frequent use of vasoconstrictive drugs leads to reduction of efficiency of drug, also misuse them can cause an atrophy and hypostasis of mucous membranes of a nose. When assigning Oksivina-DF, in order to avoid risk of a mucosal atrophy of a nose, it is possible to apply to treatment of chronic rhinitis only under observation of the doctor.
At frequent use of high dosages the derivatives of imidazoline can result (congestion) of nasal passes in reactive stagnation. Therefore, it is not necessary to exceed independently recommended doses and to use drug more than 5 – 7 days.
To apply with care in the coronary heart disease (CHD).

Overdose
Symptoms: when exceeding the recommended doses or accidental intake the following symptoms can appear: narrowing of pupils, nausea, vomiting, cyanosis, temperature increase, tachycardia, arrhythmia, collapse, oppression of warm activity, arterial hypertension, fluid lungs, respiratory disorders. Besides, there can be mental disorders and also the oppression of functions of the central nervous system which is followed by drowsiness, fall of temperature of a body, bradycardia, arterial hypotension, an apnoea and possible development of a coma.
Treatment: immediately appoint activated carbon (absorbent), sodium sulfate (depletive) or gastric lavage. For a lowering of arterial pressure appoint non-selective alpha adrenoblockers (phentolamine of 5 mg in saline (physiological) solution slowly in/in or 100 mg orally). Use of angiotonic means is contraindicated.
If necessary carry out febrifugal, anticonvulsant therapy and artificial ventilation of the lungs.

A form of release and packing
On 10 ml of drug in the plastic bottles droppers corked by caps with control of the first opening. On each bottle paste the label. On one bottle together with the instruction for medical use in the state and Russian languages place in a pack cardboard.

To Store storage conditions in the place protected from light, at a temperature not over 25 of 0C.
To store out of children’s reach!

Period of storage
3 years.
The period of use of drug after opening of a bottle – 15 days.
Not to apply after an expiration date.

Prescription status
Without prescription

Additional information